mTOR inhibitor introduce disitamab vedotin (RC48-ADC) rechallenge microtubule-chemotherapy resistance in HER2-low MBC patients with PI3K mutation

Overview of attention for article published in Frontiers in oncology, January 2024

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 2 X users

Readers on

mendeley: 4 Mendeley

Summary X

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 18,660 followers.

RT @FrontOncology: New research: mTOR inhibitor introduce disitamab vedotin (RC48-ADC) rechallenge microtubule-chemotherapy resistance in H…

26 Jan 2024

Reply Repost Favourite

New research: mTOR inhibitor introduce disitamab vedotin (RC48-ADC) rechallenge microtubule-chemotherapy resistance in HER2-low MBC patients with PI3K mutation: This study aimed to explore the efficacy and potential mechanisms of rechallenge… https://t.co/

26 Jan 2024

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.